Novo Nordisk Secures FDA Approval for Awiqli®, First Once-Weekly Basal Insulin for Type 2 Diabetes
Summary
Novo Nordisk announced FDA approval for Awiqli® (insulin icodec-abae), the first and only once-weekly basal insulin for adults with type 2 diabetes, with a US launch anticipated in the second half of 2026.
Key Events
-
FDA Approval for Awiqli®
The US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL for adults with type 2 diabetes.
-
First Once-Weekly Basal Insulin
Awiqli® is the first and only once-weekly, long-acting basal insulin approved by the FDA, offering a significant convenience advantage over daily injections.
-
US Launch Expected H2 2026
Novo Nordisk anticipates launching Awiqli® nationwide in the US in the second half of 2026.
-
Strong Clinical Efficacy
The approval is supported by the ONWARDS phase 3a program, which demonstrated efficacy in HbA1c reduction consistent with the daily basal insulin class, with a similar safety profile.
Analysis
This FDA approval for Awiqli® marks a significant milestone for Novo Nordisk, introducing the first and only once-weekly basal insulin for adults with type 2 diabetes. This innovation could substantially improve patient adherence and quality of life by reducing daily injections to a single weekly dose, potentially capturing significant market share in the competitive diabetes treatment landscape. The approval strengthens Novo Nordisk's leading position in diabetes care and provides a strong positive catalyst, especially as the stock is currently trading near its 52-week low. The planned US launch in the second half of 2026 positions the company for future revenue growth.
At the time of this filing, NVO was trading at $36.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $163.2B. The 52-week trading range was $35.85 to $81.44. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.